(VIANEWS) - United States Steel (X), Catalyst Pharmaceuticals (CPRX), Diodes Incorporated (DIOD) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. United States Steel (X)
57.4% sales growth and 64.3% return on equity
United States Steel Corporation manufactures and markets flat-rolled steel products in North America, Europe and Asia.
United States Steel's sales growth this year is expected to be 109.3% and a negative 3.2% for next year.
Year-on-year quarterly revenue growth grew by 119.4%, now sitting on 20.27B for the twelve trailing months.
Volume
Today's last reported volume for United States Steel is 11054200 which is 36.54% below its average volume of 17419200.
United States Steel's sales growth for the next quarter is 57.4%. The company's growth estimates for the current quarter and the next is 1966.7% and 313%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 64.3%.
Volatility
United States Steel's last day, last week, and last month's current intraday variation average was 0.12%, 4.15%, and 3.96%, respectively.
United States Steel's highest amplitude of average volatility was 5.76% (day), 7.96% (last week), and 7.66% (last month), respectively.
United States Steel's Stock Yearly Top and Bottom Value
United States Steel's stock is valued at $30.17 at 01:22 EST, way below its 52-week high of $39.25 and way higher than its 52-week low of $17.98.
United States Steel's Moving Average
United States Steel's worth is under its 50-day moving average of $33.03 and way above its 200-day moving average of $26.28.2. Catalyst Pharmaceuticals (CPRX)
26.7% sales growth and 23.42% return on equity
Catalyst Pharmaceuticals, Inc. is a biopharmaceutical firm that focuses on the development and commercialization of therapies for individuals with neurological and rare neuromuscular diseases.
Catalyst Pharmaceuticals's sales growth this year is expected to be 16.1% and 18.7% for next year.
Year-on-year quarterly revenue growth grew by 22.6%, now sitting on 133.54M for the twelve trailing months.
Volume
Today's last reported volume for Catalyst Pharmaceuticals is 841093 which is 28.95% below its average volume of 1183930.
Catalyst Pharmaceuticals's sales growth for the next quarter is 26.7%. The company's growth estimates for the ongoing quarter and the next is a negative 0% and 57.1%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 23.42%.
Volatility
Catalyst Pharmaceuticals's last day, last week, and last month's current intraday variation average was 1.16%, 1.54%, and 2.00%, respectively.
Catalyst Pharmaceuticals's highest amplitude of average volatility was 6.77% (day), 5.47% (last week), and 4.21% (last month), respectively.
Catalyst Pharmaceuticals's Stock Yearly Top and Bottom Value
Catalyst Pharmaceuticals's stock is valued at $7.82 at 01:22 EST, under its 52-week high of $8.65 and way above its 52-week low of $4.43.
Catalyst Pharmaceuticals's Moving Average
Catalyst Pharmaceuticals's worth is under its 50-day moving average of $7.95 and way higher than its 200-day moving average of $6.53.3. Diodes Incorporated (DIOD)
11.3% sales growth and 16.21% return on equity
Diodes Incorporated manufactures and supplies standard products for specific applications in discrete, analog, mixed-signal, and logic markets around the world.
Diodes Incorporated's sales growth this year is expected to be 46.5% and 8% for next year.
Year-on-year quarterly revenue growth grew by 52.3%, now sitting on 1.68B for the twelve trailing months.
Volume
Today's last reported volume for Diodes Incorporated is 529119 which is 56.99% above its average volume of 337036.
Diodes Incorporated's sales growth for the next quarter is 11.3%. The company's growth estimates for the present quarter and the next is 98.6% and 38.7%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 16.21%.
Volatility
Diodes Incorporated's last day, last week, and last month's current intraday variation average was 4.81%, 3.02%, and 2.83%, respectively.
Diodes Incorporated's highest amplitude of average volatility was 7.88% (day), 4.79% (last week), and 4.23% (last month), respectively.
Diodes Incorporated's Stock Yearly Top and Bottom Value
Diodes Incorporated's stock is valued at $73.48 at 01:22 EST, way below its 52-week high of $113.98 and higher than its 52-week low of $68.01.
Diodes Incorporated's Moving Average
Diodes Incorporated's worth is way under its 50-day moving average of $86.06 and way below its 200-day moving average of $92.39.4. A10 Networks (ATEN)
10.7% sales growth and 56.56% return on equity
A10 Networks, Inc. offers networking solutions for the United States, Japan, Asia Pacific, EMEA and other countries.
A10 Networks's sales growth this year is anticipated to be 10.1% and 8.2% for next year.
Year-on-year quarterly revenue growth grew by 15.5%, now sitting on 242.03M for the twelve trailing months.
Volume
Today's last reported volume for A10 Networks is 64263 which is 94.75% below its average volume of 1225150.
A10 Networks's sales growth for the next quarter is 10.7%. The company's growth estimates for the ongoing quarter and the next is a negative 5.6% and 25%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 56.56%.
Volatility
A10 Networks's last day, last week, and last month's current intraday variation average was 2.21%, 3.57%, and 2.35%, respectively.
A10 Networks's highest amplitude of average volatility was 4.85% (day), 4.87% (last week), and 3.61% (last month), respectively.
A10 Networks's Stock Yearly Top and Bottom Value
A10 Networks's stock is valued at $14.76 at 01:22 EST, way under its 52-week high of $19.05 and way above its 52-week low of $8.42.